NMPA Issues Charging Standards for Drug and Medical Device Registration
On May 27, the China Food and Drug Administration (“NMPA”) released its “Charging Standards for Registration of Drugs and Medical Devices” which come into force immediately. For pharmaceuticals, foreign companies will have to pay for clinical trials or marketing approvals, medical device companies have to pay for class II and III registration. This applies to new and change applications as well as the extension after five years.
For small to micro enterprises in China doing medical innovation, the NMPA has set up a preferential policy of waiving registration fees and supplementary application fees.
For more information please contact us at:
Cisema China Certification GmbH
Tel.: +49 89 4161 7389 – 00
Fax: +49 89 7484 9956
info@cisema.de
www.cisema.com
